Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03576573
Other study ID # 12-LJH-002N
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date March 27, 2019
Est. completion date December 2032

Study information

Verified date November 2023
Source MicroPort Orthopedics Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in Europe. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 143
Est. completion date December 2032
Est. primary completion date December 2032
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: To be included in the study, subjects must meet all of the following criteria: - Has previously undergone primary Total Hip Arthroscopy for any of the following: - Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia; - Inflammatory degenerative joint disease such as rheumatoid arthritis; - Correction of functional deformity - Subject was implanted with the specified combination of components, namely, any MicroPort Orthopedics or Wright Medical Technology femoral stem and PROCOTYL C Acetabular Components - Subject is willing and able to complete required study visits or assessments Previously implanted bilateral subjects can have both THAs (Total Hip Arthroscopy) enrolled in the study provided: 1. the specified combination of components were implanted in both, 2. all other aspects of the Inclusion/Exclusion Criteria are satisfied, 3. enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and 4. the subject agrees to a second Informed Consent document specific to the second THA. Prospective enrolment of a previously unimplanted hip is not permitted in this study. Exclusion Criteria: Subjects will be excluded if they meet any of the following criteria: - Subject was skeletally immature (less than 21 years of age) at time of implantation - Subject has a non-MicroPort or non-Wright Medical Technology component implanted (femoral heads, acetabular shells, acetabular liners) in the enrolled Total Hip Arthroscopy - Subject is currently enrolled in another clinical investigation which could affect the endpoints of this protocol - Subject is unwilling or unable to sign the Informed Consent document - Subject has documented substance abuse issues - Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study - Subject is currently incarcerated or has impending incarceration

Study Design


Related Conditions & MeSH terms


Intervention

Device:
PROCOTYL® C
Hip Arthroplasty

Locations

Country Name City State
Germany Elbe Kliniken Buxtehude Buxtehude

Sponsors (1)

Lead Sponsor Collaborator
MicroPort Orthopedics Inc.

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Component Survivorship The primary endpoint is to evaluate component survivorship of the PROCOTYL® C Acetabular Components out to 10 years follow-up. Percentage of hips survived with no revision or replacement at 10-year. 10 years post-operative
Secondary To determine the cumulative incidence of component revision at specified intervals out to 10 years follow-up; Percentage of hips that were revised or replaced at each of the intervals namely for Early (2-5 years), midterm (5-7 Year), and long-term (10-year) evaluation. 2-5 years, 5-7 years, and 10 years
Secondary To characterize functional scores, as assessed by Oxford Hip. The study will be reporting the final Oxford Hip score, which is a summary over 12 items. Each of these items is 5-level Likert scale such as from 'not at all' to 'totally'. 2-5 years, 5-7 years, and 10 years
Secondary To characterize functional scores, as assessed by EQ-5D-3L scores. EQ-5D-3L data will be summarized over 5 domains, namely, mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain has 3 levels: no problems, some problems, and extreme problems. 2-5 years, 5-7 years, and 10 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02314702 - Post Market Clinical Follow-Up Study Protocol for PROFEMUR® L Revision Femoral Stems
Completed NCT03271151 - Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty Phase 4
Completed NCT03272139 - Interscalene Block Versus Superior Trunk Block Phase 4
Completed NCT01407874 - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency Phase 2
Completed NCT01256216 - Signature Versus Computer Assisted Surgery Study N/A
Completed NCT03337243 - Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis N/A
Active, not recruiting NCT03294408 - Multimodal Imaging of Subchondral Bone in Knee Osteoarthritis : Predictive Model N/A
Withdrawn NCT02668211 - Radiostereometric Analysis (RSA) of the PROFEMUR® Preserve Classic Femoral Components N/A
Active, not recruiting NCT02239783 - Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems
Terminated NCT00698347 - A Clinical Investigation of the M2a-Magnumâ„¢ Hip System N/A
Completed NCT00223353 - Quantitative Gait Analysis for Clinical Decision Making N/A
Recruiting NCT04037735 - RSA-RCT: Attune S+ TKA Versus Sigma TKA N/A
Terminated NCT03575975 - 3D X-ray Motion Analysis of Ankle-foot Motion After Total Ankle Arthroplasty
Completed NCT03894514 - Multi-variable Prediction Model of Total Knee Replacement Outcome
Completed NCT02865447 - Evaluation of Bone Mineral Density Changes After Total Hip Replacement: A Two-Year Clinical and DXA Analysis
Completed NCT02967874 - Autologous Adipose-Derived Stromal Vascular Fraction Cells for Osteoarthritis Treatment Phase 1/Phase 2
Completed NCT02390336 - Mobilization With Movement in Patients With Osteoarthritis of the Hip N/A
Terminated NCT03293719 - Post-market Follow up Study of the 'BPK-S Integration' UC as Primary Implant in the Variants CoCr or Ceramic
Active, not recruiting NCT02823834 - PMCF Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular Components
Active, not recruiting NCT02351414 - Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts